0001827564-23-000002.txt : 20230321
0001827564-23-000002.hdr.sgml : 20230321
20230321190638
ACCESSION NUMBER: 0001827564-23-000002
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230317
FILED AS OF DATE: 20230321
DATE AS OF CHANGE: 20230321
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Holdbrook Mark J.
CENTRAL INDEX KEY: 0001827564
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39614
FILM NUMBER: 23750881
MAIL ADDRESS:
STREET 1: 15440 LAGUNA CANYON ROAD, SUITE 160
CITY: IRVINE
STATE: CA
ZIP: 92618
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Tarsus Pharmaceuticals, Inc.
CENTRAL INDEX KEY: 0001819790
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 814717861
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 15440 LAGUNA CANYON ROAD
CITY: IRVINE
STATE: CA
ZIP: 92618
BUSINESS PHONE: (949) 409-9820
MAIL ADDRESS:
STREET 1: 15440 LAGUNA CANYON ROAD
CITY: IRVINE
STATE: CA
ZIP: 92618
4
1
wf-form4_167943994647637.xml
FORM 4
X0407
4
2023-03-17
1
0001819790
Tarsus Pharmaceuticals, Inc.
TARS
0001827564
Holdbrook Mark J.
C/O TARSUS PHARMACEUTICALS, INC.
15440 LAGUNA CANYON ROAD, SUITE 160
IRVINE
CA
92618
0
1
0
0
V.P., Clinical Affairs
0
Common Stock
2023-03-17
4
S
0
188
13.28
D
3389
D
Common Stock
2023-03-20
4
S
0
198
12.61
D
3191
D
The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of Restricted Stock Units. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.
/s/ Leonard M. Greenstein, Attorney-in-Fact
2023-03-21